Sitagliptin ( Januvia ) was used as monotherapy or in combination with Metformin, thiazolidinedione or sulfonylurea. It is not clear whether effects are enhanced or unique when in combination with transient continuous subcutaneous Insulin infusion ( CSII ) therapy.
The aim of this study was to assess the safety and efficacy of Sitagliptin in combination with transient CSII therapy in patients with newly diagnosed type 2 diabetes.
Eighty patients with newly diagnosed type 2 diabetes from July 2011 to May 2013 were recruited into the study. These patients were randomly divided into a CSII monotherapy group ( group A, n = 40 ) or a Sitagliptin in combination with CSII therapy group ( group B, n = 40 ) and received Insulin intensive therapy.
Treatments were maintained for 2 weeks.
75g oral glucose tolerance test ( OGTT ) was performed before and after treatments, and the levels of glucose, insulin and C-peptide were examined.
The results have indicated that, compared with CSII therapy group, the level of plasma glucose significantly decreased, the levels of insulin and C-peptide strikingly increased and Homeostasis model assessment for beta-cell function ( HOMA-beta ) and Insulinogenic index ( Ins index ) were improved in the group ofSsitagliptin in combination with CSII therapy.
Above all, the incidence of hypoglycemia was lower, insulin doses were less and the rate of recovery to normal glucose tolerance ( NGT ) or impaired glucose tolerance ( IGT ) determined by 75g OGTT was higher in the latter.
In conclusion, Sitagliptin in combination with continuous subcutaneous insulin infusion therapy can be a new safe and effective therapy in patients with newly diagnosed type 2 diabetes mellitus. ( Xagena )
Yuan G et al, Endocr J 2014; Epub ahead of print